^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Non Small Cell Lung Cancer

    Related cancers:
    1d
    LUNGDOC: Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis (clinicaltrials.gov)
    P=N/A, N=133, Active, not recruiting, University Hospital, Montpellier | Trial completion date: Jul 2025 --> Dec 2026
    Trial completion date
    1d
    Identification of Palliative Care Needs and Prognostic Factors of Survival in Tailoring Appropriate Interventions in Advanced Oncological, Renal and Pulmonary Diseases (clinicaltrials.gov)
    P=N/A, N=178, Completed, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Active, not recruiting --> Completed
    Trial completion
    1d
    KEYNOTE D46: Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) (clinicaltrials.gov)
    P3, N=614, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    1d
    Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) (clinicaltrials.gov)
    P1/2, N=315, Active, not recruiting, Dizal Pharmaceuticals | Trial completion date: Jul 2025 --> Dec 2025
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Zegfrovy (sunvozertinib)
    1d
    A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) (clinicaltrials.gov)
    P3, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab)
    1d
    Profound neutrophilia as the presenting sign of GCSF-secreting, ROS1-mutant squamous cell lung cancer. (PubMed, BMJ Case Rep)
    Furthermore, this case describes a rare presentation of a ROS1 alteration in SCC of the lung. This illustrates the importance of routine comprehensive genomic profiling in lung cancer patients regardless of histology and smoking status.
    Journal
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 rearrangement
    1d
    SRC at the Crossroads of KRAS Inhibitor Resistance: Mechanisms and Therapeutic Opportunities. (PubMed, Cancer Lett)
    We also critically examine the shortcomings of early-generation SRC inhibitors in solid tumors and highlight emerging therapeutic avenues such as next-generation inhibitors, proteolysis-targeting chimera (PROTAC) degraders, and biomarker-guided combination strategies. By connecting molecular insights with preclinical and clinical findings, this review positions SRC as a therapeutically actionable vulnerability in KRAS-driven cancers and outlines a translational framework for overcoming drug resistance.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C
    1d
    miR-150 in cancer metastasis: Orchestrating migration, invasion, and angiogenesis through context-dependent mechanisms. (PubMed, Cancer Treat Res Commun)
    Therapeutically, tailored strategies employing miR-150 mimics, antagomiRs, or ceRNA-targeted inhibitors hold potential for disrupting metastatic pathways; however, challenges such as isoform-specific targeting, precise delivery, and mitigation of off-target effects remain unresolved. In our view, framing miR-150 as a "double-edged sword" in metastatic regulation provides a conceptual framework for leveraging its molecular versatility to advance precision oncology and mitigate metastatic progression, particularly in combination with emerging systemic therapies.
    Review • Journal
    |
    MIR150 (MicroRNA 150)
    1d
    KAT2A accelerates lung cancer progression through succinylation of TGFβR2. (PubMed, Tissue Cell)
    Moreover, in vivo experiments demonstrated that KAT2A knockdown markedly inhibited tumor growth. Our findings suggest that KAT2A functions as an oncogenic driver in NSCLC by modulating the succinylation of TGFβR2, underscoring its potential as a therapeutic target.
    Journal
    |
    TGFBR2 (Transforming Growth Factor Beta Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1)
    1d
    Biomarker analysis from a Phase 1/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer. (PubMed, Transl Oncol)
    In CEACAM5 HE, the ORR was greater with high versus low cCEA. Associations were observed between cCEA and cCEACAM5; IHC CEACAM5, cCEA, and cCEACAM5; IHC CEACAM5 and CEACAM5 mRNA, but not between IHC CEACAM5 and oncogenic drivers.
    P1 data • Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    tusamitamab ravtansine (SAR408701)
    1d
    Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, Novartis Pharmaceuticals
    New P1 trial
    1d
    Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC (clinicaltrials.gov)
    P2, N=318, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Initiation date: Jan 2025 --> Jun 2025
    Trial initiation date • Real-world evidence
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed